16 May 2023

**Genflow Biosciences Plc**

(“Genflow” or “the Company”)

**Notice of Annual General Meeting**

Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age, is pleased to announce that it will hold its Annual General Meeting ("AGM") at 09:00am on Thursday 8 June 2023 at the offices of Westend Corporate LLP, 6 Heddon Street, London, W1B 4BT.

The Notice of the AGM ("Notice") and 2023 Form of Proxy are now available on the Company’s website, [www.genflowbio.com](http://www.genflowbio.com), and have, where applicable, been posted to shareholders. Further details of the arrangements for this year's AGM are set out in the Notice.

As announced on 24 April 2023, the Company's Annual Report and Accounts for the year ended 31 December 2022 is also available on the website and has, where applicable, also been posted to registered shareholders.

For further information please contact:

|  |  |
| --- | --- |
| **Genflow Biosciences Plc** |  |
| **Dr Eric Leire**Chief Executive | +32 477 495 881 |
| **Clear Capital Markets Ltd** |  |
| Corporate Broker **Andrew Blaylock**  | +44 203 869 6080 |

**About Genflow**

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase our understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit [www.genflowbio.com](http://www.genflowbio.com)

-Ends-